Document Detail


A contemporary approach to thrombolytic therapy for pulmonary embolism.
MedLine Citation:
PMID:  10943588     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Successfully utilized contemporary pulmonary embolism thrombolysis reverses right heart failure rapidly and safely. This therapeutic approach may lower mortality from pulmonary embolism and reduce morbidity from chronic pulmonary hypertension. Unlike myocardial infarction thrombolysis, a 2-week 'time window' is available, during which treatment can be initiated. A high concentration of the thrombolytic agent is administered in a brief infusion lasting several hours. No special laboratory testing is needed. Currently, the only contemporary thrombolytic regimen for pulmonary embolism that is approved by the Food and Drug Administration is tissue plasminogen activator, in a dose of 100 mg/2 h. New thrombolytic agents under development for pulmonary embolism include reteplase, saruplase, and recombinant staphylokinase. Future clinical trials will require multicenter collaboration and will focus on relevant endpoints such as the reduction of mortality and recurrent venous thromboembolism.
Authors:
S Z Goldhaber
Related Documents :
9917588 - The john charnley award. prophylaxis of fat and bone marrow embolism in cemented total ...
24035298 - Equivalency of right internal thoracic artery and right gastroepiploic artery composite...
19823078 - Idiopathic (unexplained) pulmonary embolism is associated with an impaired prognosis co...
16356538 - Estimating the pretest probability threshold to justify empiric administration of hepar...
12378988 - Surgical prognosis of unruptured cerebral aneurysms. report of 40 cases in university h...
11198318 - Endovascular treatment of a noninfected anastomotic juxtarenal aortic aneurysm.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Vascular medicine (London, England)     Volume:  5     ISSN:  1358-863X     ISO Abbreviation:  Vasc Med     Publication Date:  2000  
Date Detail:
Created Date:  2000-11-13     Completed Date:  2000-11-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9610930     Medline TA:  Vasc Med     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  115-23     Citation Subset:  IM    
Affiliation:
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Fibrinolytic Agents / therapeutic use*
Hemodynamics / drug effects,  physiology
Humans
Pulmonary Embolism / drug therapy*,  physiopathology
Thrombolytic Therapy*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antisense and gene therapy to prevent restenosis.
Next Document:  Chromium, exercise, and body composition.